News Gist .News

Articles | Politics | Finance | Stocks | Crypto | AI | Technology | Science | Gaming | PC Hardware | Laptops | Smartphones | Archive

Thermo Fisher Buys Solventum's Purification and Filtration Business for $4.1 Billion

Thermo Fisher Scientific is acquiring Solventum's purification and filtration business for $4.1 billion, a deal expected to expand the company's presence in bioprocessing. The acquisition should allow Thermo to gain entry into the filtration category, where peers Danaher and Repligen are more strongly positioned. Thermo expects the deal to be dilutive in its first year of ownership but accretive by 2025.

See Also

Honeywell to Buy Pump Maker Sundyne for $2.16 Billion Δ1.72

Honeywell International is set to expand its energy business with the acquisition of Sundyne, a leading manufacturer of engineered pumps and gas compressors, as part of its efforts to strengthen its presence in the aviation, automation, and energy sectors. The deal will add to Honeywell's unit catering to the energy and petrochemical industries, while enhancing its aftermarket services business. By acquiring Sundyne, Honeywell aims to capitalize on the growing demand for industrial equipment and services.

Moderna (MRNA) Stock Is Rallying Today Δ1.70

Moderna's Court Victory has resulted in a 8% increase in stock value after a German court ruled that BioNTech and Pfizer must pay Moderna damages for infringing on its mRNA patents. The company is now seeking damages based on all sales of Comirnaty over the last three years. This move is seen as a major win for Moderna, which had been seeking compensation for what it claims are stolen intellectual property rights.

Saudi Aramco Exploring Initial Bid for BP's Castrol Unit, Source Says Δ1.70

Saudi Aramco is in the early stages of considering a potential bid for BP's lubricant business Castrol, according to a person with knowledge of the matter. The Saudi oil giant's interest comes as BP reviews its Castrol business, aiming to generate $20 billion in divestments by 2027. A successful acquisition could help Aramco expand its presence in the global lubricants market.

Rocket to Buy Real Estate Broker Redfin for $1.75 Billion Δ1.70

Rocket Cos.'s acquisition of Redfin Corp., valued at $1.75 billion, signals a significant shift in the property market as the financial technology group delves deeper into the industry with a new listing site. The deal represents a premium of 63% over Redfin's common stock price, indicating investor confidence in Rocket's ability to integrate home search with its existing platform. By acquiring Redfin, Rocket aims to accelerate its purchase and AI strategy, aiming for $200 million in run-rate synergies by 2027.

MODerna Stock Zooms Nearly 16% Higher on Hump Day Δ1.69

Moderna's stock price surged nearly 16% higher following a court ruling in Germany that found Pfizer and BioNTech had violated a COVID-19 patent held by Moderna. The company, best known for producing the Spikevax vaccine, will receive compensation from its rivals for the use of the patent in developing their own COVID jab, Comirnaty. This decision establishes a significant precedent for intellectual property protection in the pharmaceutical industry.

VKTX Stock Soars on Rumors of Pfizer Acquisition Deal Δ1.69

Viking Therapeutics, Inc. (NASDAQ:VKTX) saw a significant increase in share price by 9.30 percent to close at $28.09 apiece on Tuesday, driven by rumors of a potential acquisition deal with pharmaceutical giant Pfizer Inc. The company has announced participation in two investor conferences, sparking hopes for new developments and possible partnerships. Despite the recent earnings report showing widening net losses, investors have expressed optimism about the company's future prospects.

Philip Morris Weighs Cigar Sale Amid Smoke-Free Shift Δ1.69

Philip Morris International Inc. is considering selling its U.S. cigar business as part of its broader strategy to pivot towards smoke-free products. The company is reportedly seeking over $1 billion for the cigar division, which was acquired through the recent $16 billion purchase of Swedish Match AB. This move aligns with Philip Morris's goal to reduce its reliance on traditional tobacco products, with a target of smoke-free items making up two-thirds of sales by 2030.

Chimerix, Inc. (CMRX) Soared Last Week Δ1.69

Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company, experienced a significant surge in share price last week, jumping 60.5 percent to $8.43 per share, following the announcement of its acquisition by Jazz Pharmaceuticals for $935 million. The deal grants Jazz access to Chimerix's clinical asset dordaviprone, a novel treatment for H3 K27M-mutant diffuse glioma, a rare and high-grade brain tumor. The acquisition is expected to be completed in the second quarter of this year.

Saudi Aramco Exploring Initial Bid for BP's Castrol Unit, Source Says Δ1.69

BP's lubricant business Castrol is expected to be worth $6 billion to $8 billion, according to analyst Ashley Kelty. The business has been put up for sale as part of a strategic review by the company. BP has underperformed peers and faced increasing pressure to change strategy after activist investor Elliott Investment Management built a 5% stake in the company.

Walgreens to Be Taken Private in $10 Billion Buyout by Sycamore Δ1.69

Walgreens Boots Alliance will be taken private by private equity firm Sycamore Partners in a $10 billion deal, ending nearly a century of public trading for the second-largest U.S. pharmacy chain. The acquisition reflects Walgreens' struggles with declining prescription margins, increasing debt, and competition from bigger stores. The purchase price represents a 90% drop from the company's $100 billion value in 2015.

Walgreens Acquisition Could Spark Consolidation in Healthcare Industry Δ1.69

Sycamore Partners' potential buyout of Walgreens Boots Alliance Inc. could lead to a significant shift in the pharmacy retailer's business segments, potentially sparking consolidation in the healthcare industry as private credit lenders and banks vie for financing opportunities. The acquisition plans involve splitting up Walgreens into separate businesses, which could impact the company's operational capacity and strategic direction. Private equity firms have a history of restructuring companies through acquisitions.

Pfizer Inc. (PFE) The Best Cheap Dividend Stock To Buy Right Now Δ1.69

Pfizer Inc.'s (NYSE:PFE) dividend yield currently stands at around 4%, significantly higher than many of its peers, making it an attractive option for income-seeking investors. Despite the recent market rally, Pfizer's stock has remained relatively stable, with a beta score indicating lower volatility compared to other large-cap pharmaceutical companies. However, this stability may be due in part to its diversified portfolio and substantial cash reserves.

Chemicals Company Ascend Performance Gets Rescue Financing Δ1.69

Ascend Performance Materials Inc. has secured fresh financing from some of its creditors, providing the company with time to restructure its debt and address concerns over its financial health. The new loan will give Ascend a much-needed lifeline as it navigates earnings pressure and approaches a loan maturity next year. By obtaining this rescue financing, the chemicals firm aims to shore up its liquidity pool and make progress on restructuring its debt.

Mars Announces $25-30 Billion Bond Offering to Finance Kellanova Acquisition Δ1.69

Mars has announced an eight-part investment-grade bond offering worth between $25 billion to $30 billion to finance its takeover of Pringles maker Kellanova, one of the largest acquisition financing deals expected this year. The bond offering will help Mars complete its acquisition of Kellanova, a deal reportedly valued at over $3 billion. The move is part of Mars' efforts to expand its portfolio through strategic acquisitions.

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Δ1.68

Sunshine Biopharma Inc. has announced the acquisition of rights to two gastrointestinal drugs, including Prucalopride, a generic version of Resotran, which is indicated for the treatment of chronic idiopathic constipation in adult women. The company's plan to launch these drugs positions it well to capitalize on the growing demand in the chronic idiopathic constipation market, expected to grow at a Compound Annual Growth Rate (CAGR) of 4.64% from 2024 to 2034. By expanding its portfolio of life-saving medicines, Sunshine Biopharma aims to solidify its position as a leading player in Canada's pharmaceutical industry.

Armis Buys Otorio for $120M to Beef up Cybersecurity in Physical Spaces Δ1.68

Armis is acquiring Otorio, a specialist in securing industrial and physical environments, for $120 million in cash and shares. The deal will integrate Otorio's flagship product, Titan, into Armis' Centrix platform, expanding its focus from cloud services to industrial machinery and wider industrial environments. By combining their technologies, Armis aims to provide more comprehensive cybersecurity solutions across various physical spaces.

Microsoft Just Handed IPO Prospect Anduril a $22 Billion Opportunity. Δ1.68

Anduril Industries has taken the defense industry by storm with its recent announcement of partnering with Microsoft to develop the Integrated Visual Augmentation System (IVAS) for the U.S. Army, which is expected to be worth $22 billion over 10 years. The deal marks a significant shift in Anduril's strategy, as it takes over full responsibility for developing and producing IVAS from Microsoft, which previously handled all roles. With this partnership, Anduril will be able to leverage its expertise in artificial intelligence-powered drones to enhance the capabilities of IVAS.

Protalix BioTherapeutics Announces Fiscal Year 2024 Financial and Business Results on March 17 Δ1.68

Protalix BioTherapeutics, Inc. will release its financial results for the fiscal year ended December 31, 2024, and provide a business and clinical update on March 17, 2025, marking a significant milestone in the company's journey as it continues to push the boundaries of recombinant therapeutic protein development. The announcement comes after Protalix has already gained FDA approval for its innovative ProCellEx plant cell-based expression system, paving the way for future product launches. As the company looks to the future, investors and stakeholders will be eagerly awaiting insights into its progress.

Rocket Companies to Acquire Redfin for $1.75B Δ1.68

Rocket Companies is set to acquire Redfin in an all-stock transaction valued at $1.75 billion, aiming to integrate their home search services with financing solutions. This merger is expected to enhance the home-buying experience, allowing customers to easily navigate from property search to loan qualification. Despite recent struggles in Redfin's stock performance and missed earnings expectations, the acquisition positions Rocket Companies to capitalize on Redfin's established market presence.

Cassava Sciences Reports Financial Results and Business Update Period. Δ1.68

Cassava Sciences, Inc. reported financial results for the year ended December 31, 2024, with a net loss of $24.3 million, or $0.53 per share (basic), compared to $97.2 million in 2023. The company's cash and cash equivalents were $128.6 million at the end of 2024, with no debt, indicating improved financial management. Cassava Sciences is preparing to report the topline results of its Phase 3 study REFOCUS-ALZ, which will inform its next steps for simufilam in Alzheimer's disease.

Sun Pharmaceutical Industries Ltd. Buys US-Based Checkpoint for $355 Million Δ1.68

Sun Pharmaceutical Industries Ltd. has agreed to buy US-based immunotherapy and oncology firm Checkpoint Therapeutics Inc. for an upfront payment of $355 million, as India’s largest drugmaker bolsters its specialty therapy portfolio. The acquisition is the firm’s second in less than three months, as it tries to rapidly diversify beyond generic drugs and build out a portfolio of novel therapies. This deal further underscores Sun Pharma's expansion into the lucrative US market for specialty medicines.

Novo Nordisk to Sell Wegovy for $499 a Month to Cash-Paying US Customers Δ1.68

Novo Nordisk has announced that it will begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, marking a significant shift in the competitive dynamic of the U.S. obesity drug market. This move comes as rival Eli Lilly has cut the price for its weight-loss drug Zepbound and expanded its direct-to-consumer sales through its website. The Danish drugmaker will also offer home delivery for Wegovy, which can cost patients over $1,000 a month without insurance coverage.

Rocket Companies to Acquire Redfin in $1.75B Deal Δ1.68

Rocket Companies is set to acquire Redfin in a $1.75 billion all-stock transaction, which will merge the two companies under a unified vision to enhance the home buying and selling experience. The deal values Redfin at a 63% premium to its recent trading price, with Rocket Companies shareholders expected to own 95% of the new entity. This acquisition follows a period of financial struggles for Redfin, with significant stock price fluctuations and disappointing earnings reports.

Safra Sarasin Group to Buy Majority Stake in Saxo Bank Δ1.68

Swiss private bank J. Safra Sarasin Group has finalized an agreement to purchase a 70% stake in Saxo Bank, a deal valued at approximately 1.1 billion euros ($1.19 billion). This acquisition includes buying out Finnish Mandatum's 19.8% share and the 49.9% stake held by Chinese group Geely, while Saxo Bank's CEO Kim Fournais will continue in his role and maintain a 28% ownership. The transaction highlights a strategic move within the financial sector, as J. Safra Sarasin aims to enhance its digital trading and investment offerings.

ServiceNow to Buy Moveworks for $2.85B to Grow Its AI Portfolio Δ1.68

ServiceNow has announced its acquisition of Moveworks for $2.85 billion, enhancing its portfolio of enterprise automation and AI tools. The deal, expected to close in the second half of 2025, aims to integrate Moveworks’ AI capabilities with ServiceNow’s existing workflow automation technologies, potentially transforming enterprise-wide AI adoption. With a strong client base and a talented team, Moveworks is positioned to accelerate innovation and improve user experiences across various business functions.